Clinical Trial Update: Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating ABT-874 for efficacy and safety in adults with moderate to severe chronic plaque psoriasis. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• ABT-874 (briakinumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Psoriasis | Phase 2 | Status: COMPLETED